|  | ECLS (N=298) | ECMELLA (N=152) | Overall (N=450) |
| --- | --- | --- | --- |
| **Age (years)** |  |  |  |
| Mean (SD) | 62.9 (13.8) | 59.9 (12.5) | 61.9 (13.4) |
| Median [Min, Max] | 65.0 [18.0, 87.0] | 61.0 [21.0, 83.0] | 64.0 [18.0, 87.0] |
| Missing | 0 (0%) | 1 (0.7%) | 1 (0.2%) |
| **Sex** |  |  |  |
| Female | 88 (29.5%) | 30 (19.7%) | 118 (26.2%) |
| Male | 210 (70.5%) | 122 (80.3%) | 332 (73.8%) |
| **BMI** |  |  |  |
| Mean (SD) | 28.0 (5.91) | 27.4 (5.86) | 27.8 (5.89) |
| Median [Min, Max] | 27.3 [15.8, 49.6] | 26.2 [15.9, 51.5] | 26.7 [15.8, 51.5] |
| Missing | 37 (12.4%) | 4 (2.6%) | 41 (9.1%) |
| **Diabetes (Type II)** |  |  |  |
| Yes | 84 (28.2%) | 61 (40.1%) | 145 (32.2%) |
| No | 201 (67.4%) | 77 (50.7%) | 278 (61.8%) |
| Missing | 13 (4.4%) | 14 (9.2%) | 27 (6.0%) |
| **Chronic kidney disease** |  |  |  |
| Yes | 75 (25.2%) | 36 (23.7%) | 111 (24.7%) |
| No | 208 (69.8%) | 100 (65.8%) | 308 (68.4%) |
| Missing | 15 (5.0%) | 16 (10.5%) | 31 (6.9%) |
| **Chronic kidney disease (stage)ᵃ** |  |  |  |
| 2 | 12 (4.0%) | 11 (7.2%) | 23 (5.1%) |
| 3 | 22 (7.4%) | 4 (2.6%) | 26 (5.8%) |
| 4 | 15 (5.0%) | 10 (6.6%) | 25 (5.6%) |
| 5 | 10 (3.4%) | 2 (1.3%) | 12 (2.7%) |
| 6 | 4 (1.3%) | 2 (1.3%) | 6 (1.3%) |
| Missing | 235 (78.9%) | 123 (80.9%) | 358 (79.6%) |
| **Chronic obstructive pulmonary disease** |  |  |  |
| Yes | 34 (11.4%) | 17 (11.2%) | 51 (11.3%) |
| No | 251 (84.2%) | 110 (72.4%) | 361 (80.2%) |
| Missing | 13 (4.4%) | 25 (16.4%) | 38 (8.4%) |
| **Chronic obstructive pulmonary disease (stage)** |  |  |  |
| 1 | 5 (1.7%) | 0 (0%) | 5 (1.1%) |
| 2 | 5 (1.7%) | 3 (2.0%) | 8 (1.8%) |
| 3 | 6 (2.0%) | 4 (2.6%) | 10 (2.2%) |
| 4 | 3 (1.0%) | 1 (0.7%) | 4 (0.9%) |
| 5 | 14 (4.7%) | 9 (5.9%) | 23 (5.1%) |
| Missing | 265 (88.9%) | 135 (88.8%) | 400 (88.9%) |
| **Lactate (mg/dL)** |  |  |  |
| Mean (SD) | 74.1 (53.8) | 67.2 (45.2) | 71.9 (51.2) |
| Median [Min, Max] | 62.5 [4.00, 229] | 58.5 [4.00, 200] | 61.0 [4.00, 229] |
| Missing | 46 (15.4%) | 32 (21.1%) | 78 (17.3%) |
| **Median pH** |  |  |  |
| Mean (SD) | 7.44 (0.0636) | 7.43 (0.0719) | 7.43 (0.0670) |
| Median [Min, Max] | 7.44 [7.17, 7.64] | 7.44 [7.04, 7.56] | 7.44 [7.04, 7.64] |
| Missing | 70 (23.5%) | 10 (6.6%) | 80 (17.8%) |
| **Vasoactive-inotropic score (VIS)ᵇ** |  |  |  |
| Mean (SD) | 40.0 (38.1) | 41.8 (40.5) | 40.6 (38.9) |
| Median [Min, Max] | 30.0 [0, 175] | 33.0 [0, 175] | 31.1 [0, 175] |
| **RRT required (prior to tMCS)** |  |  |  |
| Yes | 37 (12.4%) | 15 (9.9%) | 52 (11.6%) |
| No | 257 (86.2%) | 133 (87.5%) | 390 (86.7%) |
| Missing | 4 (1.3%) | 4 (2.6%) | 8 (1.8%) |
| **Median creatinine (mg/dL)** |  |  |  |
| Mean (SD) | 1.94 (1.05) | 1.75 (0.938) | 1.87 (1.01) |
| Median [Min, Max] | 1.80 [0.500, 6.00] | 1.60 [0.400, 6.00] | 1.70 [0.400, 6.00] |
| Missing | 68 (22.8%) | 13 (8.6%) | 81 (18.0%) |
| **Etiology of cardiogenic shock** |  |  |  |
| AHF | 50 (16.8%) | 62 (40.8%) | 112 (24.9%) |
| AMICS | 50 (16.8%) | 48 (31.6%) | 98 (21.8%) |
| PCCS | 133 (44.6%) | 26 (17.1%) | 159 (35.3%) |
| Other | 64 (21.5%) | 15 (9.9%) | 79 (17.6%) |
| Missing | 1 (0.3%) | 1 (0.7%) | 2 (0.4%) |
| **Previous cardiac arrest** |  |  |  |
| Yes | 102 (34.2%) | 64 (42.1%) | 166 (36.9%) |
| No | 196 (65.8%) | 88 (57.9%) | 284 (63.1%) |
| **eCPR** |  |  |  |
| Yes | 17 (5.7%) | 8 (5.3%) | 25 (5.6%) |
| No | 281 (94.3%) | 144 (94.7%) | 425 (94.4%) |
| **Nephrotoxic drugsᶜ** |  |  |  |
| Yes | 77 (25.8%) | 63 (41.4%) | 140 (31.1%) |
| No | 221 (74.2%) | 89 (58.6%) | 310 (68.9%) |
| ᵃ Stage 3a and 3b were coded as 3 and 4, respectively. The remaining stages were increased by one value.<br>ᵇ VIS, a weighted sum of vasopressor and inotropic medications, quantifies the amount of pharmacological cardiovascular support in patients on tMCS.<br>ᶜ Vancomycin (IV), gentamycin, or tobramycin | | | |